bi_microparts_image

Boehringer’s France restructure will cull over 300 jobs

pharmafile | December 11, 2018 | News story | Manufacturing and Production Boehringer, Sanofi, job cuts, pharma 

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon.

The restructure comes in the wake of an asset swap between Boehringer and Sanofi, with the former trading its consumer health division for the latter’s animal health arm Merial last year – a transaction worth $20 billion.

In total, Sanofi intends to axe 327 positions from a total of 2,800, which will also make room for the introduction of 32 new roles. The plan was confirmed by Jean Scheftsik de Szolnok, Boehringer’s Chairman for France, who also noted that those affected would be offered voluntary severance packages, though he could not say exactly when this would be the case.

Matt Fellows

Related Content

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for …

Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment

Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the …

Janssen and Sanofi enter agreement for potential vaccine programme

Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …

Latest content